195 related articles for article (PubMed ID: 28903520)
1. Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.
Melvin AJ; Warshaw M; Compagnucci A; Saidi Y; Harrison L; Turkova A; Tudor-Williams G;
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e109-e115. PubMed ID: 28903520
[TBL] [Abstract][Full Text] [Related]
2. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C
BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Kumar P; DeJesus E; Huhn G; Sloan L; Small CB; Edelstein H; Felizarta F; Hao R; Ross L; Stancil B; Pappa K; Ha B;
BMC Infect Dis; 2013 Jun; 13():269. PubMed ID: 23741991
[TBL] [Abstract][Full Text] [Related]
4. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
6. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
[TBL] [Abstract][Full Text] [Related]
8. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.
Natureeba P; Ades V; Luwedde F; Mwesigwa J; Plenty A; Okong P; Charlebois ED; Clark TD; Nzarubara B; Havlir DV; Achan J; Kamya MR; Cohan D; Dorsey G
J Infect Dis; 2014 Dec; 210(12):1938-45. PubMed ID: 24958908
[TBL] [Abstract][Full Text] [Related]
11. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Penazzato M; Giaquinto C
Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
[TBL] [Abstract][Full Text] [Related]
13. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment.
Wattanutchariya N; Sirisanthana V; Oberdorfer P
HIV Med; 2013 Apr; 14(4):226-32. PubMed ID: 23094820
[TBL] [Abstract][Full Text] [Related]
15. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
Harrison L; Melvin A; Fiscus S; Saidi Y; Nastouli E; Harper L; Compagnucci A; Babiker A; McKinney R; Gibb D; Tudor-Williams G;
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):42-53. PubMed ID: 26322666
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
19. Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Madden E; Lee G; Kotler DP; Wanke C; Lewis CE; Tracy R; Heymsfield S; Shlipak MG; Bacchetti P; Scherzer R; Grunfeld C
AIDS; 2008 Mar; 22(6):707-15. PubMed ID: 18356600
[TBL] [Abstract][Full Text] [Related]
20. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]